NASDAQ : ENGN
enGene Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · Canada
Last price 1.53 USD (Oct 30, 2026, 4:00 PM EDT) · Market cap 102.53M
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 102.53M |
| Enterprise Value | -130.51M |
Dates
| Measure | Value |
|---|
| Earnings Date | Dec 21, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 67.02M |
| Shares Outstanding | 67.02M |
| Shares Change (YoY) | +30.65% |
| Shares Change (QoQ) | +0.01% |
| Owned by Insiders (%) | 0.25% |
| Owned by Institutions (%) | 32.83% |
| Float | 33.03M |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | n/a |
| PB Ratio | 0.45 |
| P/TBV Ratio | 0.45 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 10.21 |
| Quick Ratio | 9.89 |
| Debt / Equity | 0.14 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -44.51 |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -60.50% |
| Return on Assets (ROA) | -31.99% |
| Return on Invested Capital (ROIC) | -34.46% |
| Return on Capital Employed (ROCE) | -52.33% |
| Weighted Average Cost of Capital (WACC) | 3.81% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.59M |
| Employee Count | 82 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | -497,000 |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | -0.28 |
| 52-Week Price Change | -79.13% |
| 50-Day Moving Average | 1.80 |
| 200-Day Moving Average | 4.37 |
| Relative Strength Index (RSI) | 37.04 |
| Average Volume (20 Days) | 834,847 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 1.50M |
| Short Previous Month | 1.39M |
| Short % of Shares Out | 2.24% |
| Short % of Float | 4.55% |
| Short Ratio (days to cover) | 1.91 |
Incomestatement
| Measure | Value |
|---|
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -136.65M |
| Pretax Income | -130.86M |
| Net Income | -130.36M |
| EBITDA | -135.93M |
| EBIT | -136.65M |
| Earnings Per Share (EPS) | -$2.02 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 266.32M |
| Total Debt | 33.27M |
| Net Cash | 233.05M |
| Net Cash Per Share | $3.48 |
| Equity (Book Value) | 230.29M |
| Book Value Per Share | 3.44 |
| Working Capital | 250.69M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -103.31M |
| Capital Expenditures | -688,000 |
| Depreciation & Amortization | 718,000 |
| Net Borrowing | 1.95M |
| Free Cash Flow | -104.00M |
| FCF Per Share | -$1.55 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -30.65% |
| Shareholder Yield | -30.65% |
| Earnings Yield | -132.06% |
| FCF Yield | -101.43% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | $3.29 |
| Price Target Difference | 114.77% |
| Analyst Consensus | Buy |
| Analyst Count | 9 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Measure | Value |
|---|
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |